Login / Signup

Open-label pilot study of ranolazine for cramps in amyotrophic lateral sclerosis.

Swathy ChandrashekharAnai C HamasakiRebecca ClayAyla McCalleyLaura HerbelinMamatha PasnoorOmar JawdatMazen M DimachkieRichard J BarohnJeffrey M Statland
Published in: Muscle & nerve (2022)
Ranolazine was well tolerated in ALS up to 2000 mg/day, with gastrointestinal side effects being the most frequent. Ranolazine reduced cramp frequency and severity, supporting its investigation for muscle cramps in a future placebo-controlled trial.
Keyphrases
  • open label
  • study protocol
  • clinical trial
  • skeletal muscle
  • current status
  • double blind
  • phase ii
  • amyotrophic lateral sclerosis
  • phase ii study
  • randomized controlled trial
  • rectal cancer
  • placebo controlled